The pathophysiology of vitiligo is becoming increasingly clarified. In non-segmental vitiligo,
early factors include activation of innate immunity, inflammasome activation, oxidative stress …

Vitiligo is an autoimmune disease of the skin characterized by patchy depigmentation.
Current treatments are moderately effective at reversing disease by suppressing …

Vitiligo is an acquired chronic depigmenting disorder of the skin, with an estimated
prevalence of 0.5% of the general population, characterized by the development of white …

Vitiligo is an autoimmune disease of the skin characterized by epidermal melanocyte loss
resulting in white patches, with an approximate prevalence of 0.5–2% worldwide. Several …

Vitiligo is a common, disfiguring autoimmune disease that negatively affects patients' self-
esteem and quality of life. 1, 2 Existing vitiligo treatments, which are used off-label, are …

Vitiligo is a chronic inflammatory skin disease leading to the loss of epidermal melanocytes.
To date, treatment options for vitiligo patients are limited, lack sustained efficacy, and are …

Vitiligo is the most common depigmenting disorder affecting 0.1%–2% of the population
worldwide. The characteristic white patches result from the selective loss of melanocytes …

Vitiligo is an acquired chronic pigmentary disorder affecting the melanocytes, mainly in the
skin and mucosae. It occurs due to the dynamic interaction between genetic and …

Vitiligo is the most common acquired pigmentary disorder, which afflicts 0.5%–1% of the
world population, and is characterized by depigmented skin patches resulting from …

Vitiligo, a common depigmenting skin disorder, has an estimated prevalence of 0.5–2% of
the population worldwide. The disease is characterized by the selective loss of melanocytes …